Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27962539 | 0.90 | ATR (0.43) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL29626780 | 0.90 | ATR (0.43) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL28741827 | 0.90 | ATR (0.43) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL22945805 | 0.90 | ATR (0.43) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL27955914 | 0.89 | ATR (0.42) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL2808080 | 0.89 | ATR (0.44) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL12596124 | 0.87 | AAK1 (0.41) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL12541193 | 0.87 | AAK1 (0.41) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL12695294 | 0.87 | RAB9A (0.42) | ATRGSK3BDYRK1AAAK1MAPK1 | |
| SCHEMBL21199963 | 0.85 | AAK1 (0.41) | ATRGSK3BDYRK1AAAK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | ATR 3464/4885GSK3B 547/4885DYRK1A 4042/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | ATR 2483/4885GSK3B 539/4885DYRK1A 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.